The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

Evidence in Practice

Wednesday, 10 April 2019
A large study in the USA has found that starting treatment for sleep apnoea as soon as possible after a stroke or a transient ischaemic attack (TIA) significantly improves speech impairment and other neurological symptoms as well as walking and other physical functioning. Continuous Positive Airway Pressure (CPAP) therapy was shown to provide even greater benefits than tPA (tissue plasminogen activator) which is a NICE recommended drug treatment for stroke.
Topics covered:
Monday, 08 April 2019
Our regular Evidence in Practice feature summarizes recent scientific papers focusing on different aspects of cardiovascular medicine. This month we feature recent research showing that anti-inflammatory biological drugs used to treat severe psoriasis have the potential to prevent heart in patients with the condition. Over one year of treatment, biological therapy improved coronary artery plaques in a manner similar to a low-dose statin.
Monday, 01 April 2019
The Public Health England (PHE) action plan for 2017-181 outlined the scale of the cardiovascular disease (CVD) issue we face here in the UK. Affecting around 7 million people, CVD remains a significant cause of disability and death. In England, we know that it is responsible for one in four premature deaths and over a quarter of all deaths, which not only affect the individual but also their families, and impact the wider community too. Healthcare costs associated with CVD are estimated at £8.96 billion and non-healthcare costs at about £4.04 billion. 2 A recent report discusses the evidence for the success of population-based CVD prevention programmes in reducing the burden of illness for individuals and society.
Monday, 01 April 2019
The NHS Health Check is a national programme offering a health check-up every five years to adults in England aged 40 to 74 without a pre-existing cardiovascular condition. One of the largest prevention programmes of its type in the world, the programme is designed to help prevent and detect early signs of heart disease, stroke, kidney disease, type 2 diabetes and dementia. 1 This article reviews the evidence that has accumulated since the programme was established.
Thursday, 07 February 2019
Consumption of moderate amounts of full fat dairy products is associated with lower risk of mortality and major cardiovascular disease events in a diverse multinational cohort, in a study published recently in the Lancet.
Thursday, 07 February 2019
Results from the DECLARE study show that the SGLT-2 inhibitor dapagliflozin reduces hospitalisation for heart failure or CV death with no increase in major CV events compared with placebo in a broad population of over 17,000 patients with type 2 diabetes. These are important findings, and more or less consistent with findings noted with other SGLT-2 inhibitors.
Topics covered:
Thursday, 07 February 2019
Loss of muscle and body weight (or cachexia) is associated with disability after stroke, in the first study to prospectively investigate the development of cachexia in patients after acute stroke. The study showed that the amount of skeletal muscle throughout the body declines after stroke, which could require treatment options such as dietary supplementation and exercise training to prevent muscle wasting.
Topics covered:
Thursday, 17 January 2019
Approximately one third of all stroke patients have diabetes, according to a large meta-analysis and literature review. Diabetes is associated with poorer stroke outcomes compared with people without diabetes.
Topics covered:

Article search and filter